Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to -$4.5 million.

  • Immunocore Holdings' Cash from Operations fell 12109.15% to -$4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 6412.77%. This contributed to the annual value of $26.1 million for FY2024, which is 78642.86% up from last year.
  • As of Q3 2025, Immunocore Holdings' Cash from Operations stood at -$4.5 million, which was down 12109.15% from $26.0 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Cash from Operations high stood at $26.0 million for Q2 2025, and its period low was -$35.8 million during Q1 2021.
  • In the last 5 years, Immunocore Holdings' Cash from Operations had a median value of -$2.2 million in 2023 and averaged -$2.7 million.
  • The largest annual percentage gain for Immunocore Holdings' Cash from Operations in the last 5 years was 5206000.0% (2024), contrasted with its biggest fall of 14352.41% (2024).
  • Over the past 5 years, Immunocore Holdings' Cash from Operations (Quarter) stood at -$35.6 million in 2021, then soared by 51.51% to -$17.3 million in 2022, then decreased by 2.59% to -$17.7 million in 2023, then grew by 21.33% to -$14.0 million in 2024, then soared by 68.06% to -$4.5 million in 2025.
  • Its Cash from Operations was -$4.5 million in Q3 2025, compared to $26.0 million in Q2 2025 and $435000.0 in Q1 2025.